Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with ω-3 or ω-6 fatty acids and corticosteroids

References

• Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995; 3: 38–61
   Google Scholar
• Frystyk J, Skjærbæk C, Dinesen B, Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 1994; 348: 185–91
   PubMed Web of Science ®Google Scholar
• Tenore A, Berman WF, Parks JS, Bongiovanni AM. Basal and stimulated serum growth hormone concentrations in inflammatory bowel disease. J Clin Endocrinol Metab 1977; 44: 622–8
   PubMed Web of Science ®Google Scholar
• Braegger CP, Torresani T, Murch SH, Savage MO, Walker-Smith JA, MacDonald TT. Urinary growth hormone in growth-impaired children with chronic inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16: 49–52
   PubMed Web of Science ®Google Scholar
• Farthing MJ, Campbell CA, Walker-Smith J, Edwards CR, Rees LH, Dawson AM. Nocturnal growth hormone and gonadotrophin secretion in growth retarded children with Crohn's disease. Gut 1981; 22: 933–8
   PubMed Web of Science ®Google Scholar
• Grønbæk H, Thøgersen T, Frystyk J, Vilstrup H, Flyvbjerg A, Dahlerup JF. Low free and total insulin-like growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment. Am J Gastroenterol 2002; 97: 673–8
   PubMed Web of Science ®Google Scholar
• Beattie RM, Camacho-Hübner C, Wacharasindhu S, Cotterill AM, Walker-Smith JA, Savage MO. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol (Oxf) 1998; 49: 483–9
   PubMed Web of Science ®Google Scholar
• Corkins MR, Gohil AD, Fitzgerald JF. The insulin-like growth factor axis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2003; 36: 228–34
   PubMed Web of Science ®Google Scholar
• Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res 2001; 11: 364–7
   PubMed Web of Science ®Google Scholar
• Bannerjee K, Camacho-Hübner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004; 38: 270–5
   PubMed Web of Science ®Google Scholar
• Støving RK, Hangaard J, Hagen C, Flyvbjerg A. Low levels of the 150-kD insulin-like growth factor binding protein 3 ternary complex in patients with anorexia nervosa: effect of partial weight recovery. Horm Res 2003; 60: 43–8
   PubMedGoogle Scholar
• Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80–101
   PubMed Web of Science ®Google Scholar
• Underwood LE. Nutritional regulation of IGF-I and IGFBPs. J Pediatr Endocrinol Metab 1996; 9(Suppl 3)303–12
   PubMed Web of Science ®Google Scholar
• Nørrelund H, Frystyk J, Jørgensen JO, Møller N, Christiansen JS, Ørskov H, et al. The effect of growth hormone on the insulin-like growth factor system during fasting. J Clin Endocrinol Metab 2003; 88: 3292–8
   PubMed Web of Science ®Google Scholar
• O'Morain C, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. Br Med J 1984; 288: 1859–62
   PubMed Web of Science ®Google Scholar
• Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease?. Scand J Gastroenterol 2001; 36: 383–8
   PubMed Web of Science ®Google Scholar
• Fernández-Bañares F, Cabré E, Esteve-Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr 1995; 19: 356–64
   PubMed Web of Science ®Google Scholar
• Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995; 108: 1056–67
   PubMed Web of Science ®Google Scholar
• Messori A, Trallori G, D'Albasio G, Milla M, Vannozzi G, Pacini F. Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. Scand J Gastroenterol 1996; 31: 267–72
   PubMed Web of Science ®Google Scholar
• Gassull MA, Fernández-Bañares F, Cabré E, Papo M, Giaffer MH, Sánchez-Lombraña JL, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double-blind randomised multicentre European trial. Gut 2002; 51: 164–8
   PubMed Web of Science ®Google Scholar
• Lorenz R, Weber PC, Szimnau P, Heldwein W, Strasser T, Löschke K. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease: a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med 1989; 225(Suppl 731)225–32
   Web of Science ®Google Scholar
• Frystyk J, Dinesen B, Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Reg 1995; 5: 169–76
   PubMedGoogle Scholar
• Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW, et al. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 2003; 88: 132–5
   PubMed Web of Science ®Google Scholar
• Westwood M, Gibson JM, Davies AJ, Young RJ, White A. The phosphorylation pattern of insulin-like growth factor-binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy. J Clin Endocrinol Metab 1994; 79: 1735–41
   PubMed Web of Science ®Google Scholar
• Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulin-like growth factor binding proteins using Western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 1986; 154: 138–43
   PubMed Web of Science ®Google Scholar
• Flyvbjerg A, Kessler U, Dorka B, Funk B, Ørskov H, Kiess W. Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia 1992; 35: 589–93
   PubMed Web of Science ®Google Scholar
• Lamson G, Giudice LC, Rosenfeld RG. A simple assay for proteolysis of IGFBP-3. J Clin Endocrinol Metab 1991; 72: 1391–3
   PubMed Web of Science ®Google Scholar
• Wolf M, Bohm S, Brand M, Kreymann G. Proinflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 1996; 135: 729–37
   PubMed Web of Science ®Google Scholar
• Ballinger A. Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res 2002; 58(Suppl 1)7–10
   PubMedGoogle Scholar
• De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001; 142: 4818–26
   PubMed Web of Science ®Google Scholar
• Thomas AG, Holly JM, Taylor F, Miller V. Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease. Gut 1993; 34: 944–7
   PubMed Web of Science ®Google Scholar
• Akobeng AI, Clayton PE, Miller V, Hall CM, Thomas AG. Low serum concentrations of insulin-like growth factor-I in children with active Crohn disease: effect of enteral nutritional support and glutamine supplementation. Scand J Gastroenterol 2002; 37: 1422–7
   PubMed Web of Science ®Google Scholar
• Skjærbæk C, Frystyk J, Ørskov H, Kissmeyer-Nielsen P, Jensen MB, Laurberg S, et al. Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis. J Clin Endocrinol Metab 1998; 83: 2445–9
   PubMed Web of Science ®Google Scholar
• Cwyfan Hughes SC, Cotterill AM, Molloy AR, Cassell TB, Braude N, Hinds CJ, et al. The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery. J Endocrinol 1992; 135: 135–45
   PubMed Web of Science ®Google Scholar
• Davenport ML, Isley WL, Pucilowska JB, Pemberton LB, Lyman B, Underwood LE, et al. Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. J Clin Endocrinol Metab 1992; 75: 590–5
   PubMed Web of Science ®Google Scholar
• Davies SC, Wass JA, Ross RJ, Cotterill AM, Buchanan CR, Coulson VJ, et al. The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol 1991; 130: 469–73
   PubMed Web of Science ®Google Scholar
• Street ME, de'Angelis G, Camacho-Hübner C, Giovannelli G, Ziveri MA, Bacchini PL, et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res 2004; 61: 159–64
   PubMedGoogle Scholar
• De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99: 643–50
   PubMed Web of Science ®Google Scholar
• Fernández-Bañares F, Cabré E, González-Huix F, Gassull MA. Enteral nutrition as primary therapy in Crohn's disease. Gut 1994; 35(Suppl 1)S55–S9
   PubMed Web of Science ®Google Scholar
• Cabré E, Gassull MA. Nutritional and metabolic issues in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2003; 6: 569–76
   PubMed Web of Science ®Google Scholar